COMMUNIQUÉS West-GlobeNewswire

-
NeurAxis to Participate in the Lytham Partners Spring 2024 Investor Conference on May 30, 2024
21/05/2024 -
Leisure Care Creates More Connected Lives for Residents with Nationwide Rollout of Rendever
21/05/2024 -
FDA Clears Cingulate to File for Marketing Approval of CTx-1301 in the Treatment of ADHD
21/05/2024 -
Alpha Tau to Present at the Jefferies Global Healthcare Conference
21/05/2024 -
Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences
21/05/2024 -
GRI Bio Presents Positive Preclinical Data from Pipeline of NKT Cell Modulators in Development for the Treatment of Systemic Lupus Erythematosus (SLE)
21/05/2024 -
Ketabon To Present Advancements In At-Home Ketamine Therapy For Treatment-Resistant Depression At American Society Of Clinical Psychopharmacology Annual Meeting
21/05/2024 -
Positive Statistically Significant Phase 2 Clinical Trial Results of Biodexa’s Newly-licensed eRapa™ in Familial Adenomatous Polyposis (FAP) Scheduled for Presentation at the 2024 Digestive Disease Week Annual Meeting
21/05/2024 -
Palisade Bio’s Lead Product Candidate, PALI-2108 Demonstrates Local Bioactivation and Dose Dependent Efficacy Response in Preclinical Mouse Models
21/05/2024 -
MangoRx to Introduce Oral Semaglutide and Tirzepatide in Response to Increasing Patient Demand for GLP-1 Medications
21/05/2024 -
Kronos Bio Appoints Deborah Knobelman, Ph.D. as Chief Operating Officer and Chief Financial Officer
21/05/2024 -
Organovo Data Presented at Digestive Disease Week (DDW2024) Demonstrating Potential for FXR314 as Combination Therapy with Tofacitinib for Inflammatory Bowel Disease
21/05/2024 -
Ardelyx Presents Additional Data at the 2024 Digestive Disease Week Conference on IBSRELA® (tenapanor), a First-In-Class Treatment for IBS-C in Adults
21/05/2024 -
Alvotech and Dr. Reddy’s enter into collaboration for commercialization of AVT03 (denosumab), a biosimilar candidate to Prolia® & Xgeva® in the U.S., Europe and UK
21/05/2024 -
Alvotech and Dr. Reddy’s enter into collaboration for commercialization of AVT03 (denosumab), a biosimilar candidate to Prolia® & Xgeva® in the U.S., Europe and UK
21/05/2024 -
EVP and Chief Medical Officer Laurence de Moerlooze Will Be Leaving Bavarian Nordic
21/05/2024 -
Amplexd Therapeutics, Innovating to Revolutionize the Future of Non-Invasive HPV-induced Cervical Intraepithelial Neoplasia (CIN) Treatments for the Prevention of Cervical Cancer: Developed by Women for Women
21/05/2024 -
Protara Therapeutics to Present at the TD Cowen 5th Annual Oncology Innovation Summit
21/05/2024 -
AltruBio Secures up to $225M Oversubscribed Series B Financing to Advance the Clinical Development of Novel Immune Checkpoint Enhancer Program
21/05/2024
Pages